Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Apogee Therapeutics, Inc. - Common Stock (NQ:APGE)

70.23 +0.21 (+0.30%)

Streaming Delayed Price Updated: 3:50 PM EST, Jan 26, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	639,711
Open	70.00
Bid (Size)	70.23 (500)
Ask (Size)	70.27 (200)
Prev. Close	70.02
Today's Range	68.50 - 70.64
52wk Range	26.20 - 84.56
Shares Outstanding	56,367,802
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

The Great Rotation: Russell 2000’s Historic 15-Day Streak Marks a Seismic Shift in Market Leadership

Today 11:45 EST

In a move that has rewritten the record books of Wall Street, the small-cap-heavy Russell 2000 index recently concluded a historic 15-session winning streak of daily outperformance against the S&P 500....

Via MarketMinute

What Investors Should Know About a $1.5 Million Apogee Insider Sale Amid a 60% Stock Rally ↗

January 11, 2026

This clinical-stage biotech focused on long-acting antibody therapies reported a notable insider sale amid ongoing pipeline development.

Via The Motley Fool

Performance

YTD	-7.3%	-7.3%
1 Month	-9.2%	-9.2%
3 Month	+24.9%	+24.9%
6 Month	+77.1%	+77.1%
1 Year	+74.6%	+74.6%

More News

Apogee Therapeutics Chief Medical Officer Sells $817,500 Worth of Shares After Monster December Rally ↗

January 07, 2026

Via The Motley Fool

Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook

January 06, 2026

From Apogee Therapeutics

Via GlobeNewswire

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026

January 05, 2026

From Apogee Therapeutics

Via GlobeNewswire

Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results

November 10, 2025

From Apogee Therapeutics

Via GlobeNewswire

Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody

November 10, 2025

From Apogee Therapeutics

Via GlobeNewswire

Apogee Therapeutics to Participate in Upcoming Conferences

November 03, 2025

From Apogee Therapeutics

Via GlobeNewswire

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million

October 10, 2025

From Apogee Therapeutics

Via GlobeNewswire

Why Apogee Therapeutics Stock Triumphed on Thursday ↗

October 09, 2025

Via The Motley Fool

Delta Air Lines, Tilray Brands, UiPath, Akero Therapeutics, Apogee Therapeutics: Stocks Making The Biggest Moves Today ↗

October 09, 2025

Via Stocktwits

Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out ↗

October 09, 2025

Via Investor's Business Daily

Helen of Troy, Ferrari, Apogee Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

October 09, 2025

Via Benzinga

Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket ↗

October 09, 2025

Via Benzinga

Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering

October 08, 2025

From Apogee Therapeutics

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

October 08, 2025

Via Benzinga

What's going on in today's after hours session ↗

October 08, 2025

Via Chartmill

Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering

October 08, 2025

From Apogee Therapeutics

Via GlobeNewswire

Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress

September 11, 2025

From Apogee Therapeutics

Via GlobeNewswire

Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum

September 03, 2025

From Apogee Therapeutics

Via GlobeNewswire

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results

August 11, 2025

From Apogee Therapeutics

Via GlobeNewswire

Gold Falls 1%; ProKidney Shares Spike Higher ↗

July 08, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

July 07, 2025

Via Benzinga

Dow Dips 1%; Mustang Bio Shares Spike Higher ↗

July 07, 2025

Via Benzinga

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

July 07, 2025

Via Chartmill

Frequently Asked Questions

Is Apogee Therapeutics, Inc. - Common Stock publicly traded?

Yes, Apogee Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Apogee Therapeutics, Inc. - Common Stock trade on?

Apogee Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Apogee Therapeutics, Inc. - Common Stock?

The ticker symbol for Apogee Therapeutics, Inc. - Common Stock is APGE on the Nasdaq Stock Market

What is the current price of Apogee Therapeutics, Inc. - Common Stock?

The current price of Apogee Therapeutics, Inc. - Common Stock is 70.23

When was Apogee Therapeutics, Inc. - Common Stock last traded?

The last trade of Apogee Therapeutics, Inc. - Common Stock was at 01/26/26 03:50 PM ET

What is the market capitalization of Apogee Therapeutics, Inc. - Common Stock?

The market capitalization of Apogee Therapeutics, Inc. - Common Stock is 3.96B

How many shares of Apogee Therapeutics, Inc. - Common Stock are outstanding?

Apogee Therapeutics, Inc. - Common Stock has 4B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.